Osteoporosetherapie: Einfluss auf Frakturrate und Mortalität

Schlüsselwörter

Osteoporosetherapie - Leitlinie - Mortalität - Frakturreduktion

Keywords

osteoporosis therapy - guideline - mortality - fracture reduction

• Literatur

• 1 Harbeck B, Lehnert H. Personalisierte Osteoporosetherapie. Dtsch Med Wochenschr 2015; 140: 1672-1677
• 2 Eisen C. Osteoporosetherapie – Qualität der Evidenz beachten. Dtsch Med Wochenschr 2016; 141: 378
• 3 Dachverband Osteologie. DVO-Leitlinie 2014 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen. http://www.dv-osteologie.org/dvo_leitlinien/osteoporose-leitlinie-201 Letzter Zugriff am 30.03.2016
• 4 Center JR, Bliuc D, Nguyen ND et al. Osteoporosis Medication and Reduced Mortality Risk in Elderly Women and Men. J Clin Endocrinol Metab 2011; 96: 1006-1014
• 5 Beaupre LA, Morrish DW, Hanley DA et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 2011; 22: 983-991
• 6 Sambrook PN, Cameron ID, Chen JS et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 2011; 22: 2551-2556
• 7 Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010; 95: 1174-1181
• 8 Grady D, Cauley JA, Stock JL. Effect of Raloxifene on all-cause mortality. Am J Med 2010; 123: 469.e1-7
• 9 Eriksen EF, Lyles KW, Colón-Emeric CS et al. Antifracture Efficacy and Reduction of Mortality in Relation to Timing of First Dose of Zoledronic Acid After Hip Fracture. J Bone Miner Res 2009; 24: 1308-1313